Acid suppression therapy impairs sunitinib efficacy in renal cell cancer (RCC)

被引：0
|
作者：
Chu, Michael P. [1 ]
Ha, Vincent [1 ]
Ngo, Margaret [2 ]
Ghosh, Sunita [1 ]
Chambers, Carole R. [2 ]
Sawyer, Michael B. [1 ]
机构：
[1] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[2] Tom Baker Canc Clin, Calgary, AB, Canada
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-4628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4628
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SUNITINIB AND SORAFENIB FOR THE PATIENTS WITH RENAL CELL CANCER
    Yuasa, Takeshi
    Nakano, Kenji
    Kodaira, Makoto
    Urakami, Shinji
    Yamamoto, Shinya
    Yonese, Junji
    Fukui, Iwao
    Hatake, Kiyohiko
    Takahashi, Shunji
    ANNALS OF ONCOLOGY, 2010, 21 : 22 - 22
  • [32] Influence of VEGFR single nucleotide polymorphisms on the efficacy of sunitinib therapy against renal cell carcinoma
    Liu, Rui
    Wang, Xiaojie
    Li, Wei
    Shou, Tao
    Zhou, Likun
    Li, Yunfen
    Bai, Ming
    Pei, Qiang
    ONCOLOGY LETTERS, 2017, 13 (01) : 201 - 205
  • [33] Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone
    Dutcher, J. P.
    Wilding, G.
    Hudes, G. R.
    Stadler, W. M.
    Kim, S.
    Tarazi, J. C.
    Rosbrook, B.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Cardiovascular toxicity follwing sunitinib therapy in metastatic renal cell cancer: A multicenter analysis
    Di Lorenzo, G.
    De Placido, S.
    Carteni, G.
    Autorino, R.
    Gonnella, A.
    Rizzo, M.
    Perdona, S.
    Ricevuto, E.
    Aieta, M.
    Ewer, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Sequential Therapy With Sorafenib and Sunitinib in Renal Cell Carcinoma
    Dudek, Arkadiusz Z.
    Zolnierek, Jakub
    Dham, Anu
    Lindgren, Bruce R.
    Szczylik, Cezary
    CANCER, 2009, 115 (01) : 61 - 67
  • [36] Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
    Dham, A.
    Dudek, A. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Patients with metastatic papillary renal cell carcinoma (RCC) who may benefit from sunitinib therapy (tx): Results from an international metastatic RCC database.
    Kejzman, Daniel
    Gottfried, Maya
    Maimon, Natalie
    Hammers, Hans J.
    Eisenberger, Mario A.
    Carducci, Michael Anthony
    Sinibaldi, Victoria J.
    Neiman, Victoria
    Rosenbaum, Eli
    Sarid, David
    Gez, Eliahu
    Peer, Avivit
    Sella, Avishay
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Lee, Jae-Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [38] With sunitinib resistance renal cancer cells and succinic acid
    Kavsara, G. Kasarci
    Ertugrul, B.
    Bireller, S.
    Cakmakoglu, B.
    FEBS OPEN BIO, 2024, 14 : 332 - 332
  • [39] Serum proteomics classifies outcome in renal cell carcinoma (RCC) patients receiving sunitinib and erlotinib
    Robinson, K.
    Roder, J.
    Curti, B. D.
    Quinn, D. I.
    Strother, J. M.
    Grigorieva, J.
    Roder, H.
    Ryan, C. W.
    BJU INTERNATIONAL, 2012, 109 : 2 - 2
  • [40] RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
    Porta, C.
    Procopio, G.
    Sabbatini, R.
    Bearz, A.
    Chiappino, I
    Imarisio, I.
    Guadalupi, V
    Paglino, C.
    Verzoni, E.
    Ferraris, E.
    Bajetta, E.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 183 - 183
12345